Enbrel
(Etanercept)ApprovedProtein / enzyme
Etanercept is used to reduce inflammation and treat autoimmune diseases like rheumatoid arthritis, psoriasis, and Crohn's disease by blocking a protein in the body that causes swelling and joint damage.[2] Enbrel is currently approved and in use across 23 indications[4].[1]
Enbrel is one of 486 small molecule programs targeting Spondyloarthropathy. It is currently in Approved.
23
Indications
308
Total Trials
8
Active Trials
485
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 23 indications
Competition
Competitive Landscape
146 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Lexiscan
AstellasApproved
Northera
LundbeckApproved
Enbrel
IImmunex
Approved
Cardizem
BBausch Health Americas, Inc.
Approved
Aspercreme Warming
AAveritas Pharma, Inc.
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Cleviprex
Chiesi Farmaceutici S.p.A.Approved
Colcrys
Jazz PharmaceuticalsPhase 3
Cagrilintide
Novo NordiskPhase 3
Pelacarsen
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rheumatoid Arthritis44 trials
Show 41 more trials
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00796705·13 enrolled
Psoriasis33 trials
Show 30 more trials
Safety and Efficacy of Etanercept in Patients With Psoriasis
Unknown status·—·N/A·NCT02258282·80 enrolled
Ankylosing Spondylitis16 trials
Show 13 more trials
Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study
Unknown status·—·Phase 4·NCT02489760·30 enrolled
A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT02809781·250 enrolled
Etanercept (Enbrel) in Ankylosing Spondylitis
Unknown status·—·Phase 2·NCT01289743·24 enrolled
Arthritis10 trials
Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis
Withdrawn·—·Phase 1·NCT04585711
Show 7 more trials
Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)
Unknown status·—·Phase 2·NCT00844142·80 enrolled
Treatment6 trials
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
Completed·—·Phase 1·NCT05281614·20 enrolled
Show 3 more trials
Treatments Against RA and Effect on FDG-PET/CT
Completed·—·Phase 4·NCT02374021·159 enrolled
65 more indications
Psoriatic Arthritis5 trials
Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis
Completed·—·Phase 4·NCT00432406·40 enrolled
Metabolic Syndrome3 trials
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2/3·NCT00111956·56 enrolled
Type 1 Diabetes3 trials
Remission3 trials
Alzheimer's Disease3 trials
Granuloma2 trials
Etanercept for Wegener's Granulomatosis
Completed·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2/3·NCT00005007·181 enrolled
Etanercept to Treat Wegener's Granulomatosis
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001901·60 enrolled
Safety and Efficacy2 trials
Tics2 trials
Necrosis2 trials
Kidney Transplant2 trials
Clinical Trial2 trials
Acute Graft Versus Host Disease2 trials
Pneumonia2 trials
Methotrexate2 trials
Myelodysplastic Syndromes2 trials
Juvenile Idiopathic Arthritis2 trials
Immunogenicity2 trials
Arthropathy1 trial
Efficacy1 trial
Bone Marrow Transplantation1 trial
Osteoarthritis1 trial
Kawasaki Disease1 trial
Hypothermia1 trial
Stem Cell Transplant1 trial
Discoid Lupus Erythematosus1 trial
Behcet's Disease1 trial
Dermatomyositis1 trial
Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis
Terminated·—·Phase 2/3·NCT00035958·75 enrolled
Cardiovascular Disease1 trial
ART1 trial
Mild to Moderate Alzheimer's Disease1 trial
Palmoplantar Pustulosis1 trial
Pancreatic Adenocarcinoma1 trial
Renal Transplant1 trial
Glucocorticoid1 trial
Lupus Nephritis1 trial
Etanercept for the Treatment of Lupus Nephritis
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00447265·1 enrolled
Inclusion Body Myositis1 trial
Radiculopathy1 trial
MPA1 trial
SAPHO syndrome1 trial
Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome
Recruiting·NNational Institute of Geriatrics, Rheumatology and Rehabilitation, Poland·Phase 2/3·NCT06011889·60 enrolled
Fanconi Anemia1 trial
Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia
Completed·—·Phase 1·NCT00965666·3 enrolled
Temporomandibular Disorders1 trial
Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)
Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00001955·150 enrolled
Autoimmune Disease1 trial
Graft Versus Host Disease1 trial
Synovitis1 trial
Chronic Fatigue Syndrome1 trial
Corticosteroids1 trial
Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients
Completed·—·Phase 4·NCT04485325·92 enrolled
Polymyalgia Rheumatica1 trial
Etanercept Treatment in the Early Course of Polymyalgia Rheumatica
Completed·—·Phase 3·NCT00524381·40 enrolled
Unspecified3 trials
Regulatory
FDA Approval Timeline[5]
Nov 2, 1998
ENBREL
BLA BLA103795
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Enbrel drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Etanercept. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]